IOBT Net Receivables from 2010 to 2024

IOBT Stock  USD 0.89  0.04  4.71%   
IO Biotech Net Receivables yearly trend continues to be comparatively stable with very little volatility. Net Receivables is likely to outpace its year average in 2024. From the period from 2010 to 2024, IO Biotech Net Receivables quarterly data regression had r-value of  0.32 and coefficient of variation of  18.13. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
1.1 M
Current Value
1.2 M
Quarterly Volatility
239.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check IO Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IO Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 5 M, Depreciation And Amortization of 204.2 K or Interest Expense of 2.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.65. IOBT financial statements analysis is a perfect complement when working with IO Biotech Valuation or Volatility modules.
  
Check out the analysis of IO Biotech Correlation against competitors.
For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.

Latest IO Biotech's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of IO Biotech over the last few years. It is IO Biotech's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in IO Biotech's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

IOBT Net Receivables Regression Statistics

Arithmetic Mean1,318,563
Geometric Mean1,302,526
Coefficient Of Variation18.13
Mean Deviation155,775
Median1,233,000
Standard Deviation239,066
Sample Variance57.2B
Range964K
R-Value0.32
Mean Square Error55.1B
R-Squared0.10
Significance0.24
Slope17,315
Total Sum of Squares800.1B

IOBT Net Receivables History

20241.2 M
20231.1 M
20221.5 M
20212.1 M
20201.5 M

About IO Biotech Financial Statements

IO Biotech shareholders use historical fundamental indicators, such as Net Receivables, to determine how well the company is positioned to perform in the future. Although IO Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in IO Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on IO Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables1.1 M1.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.